ライフサイエンスコーパス: extrahepatic bile duct

1 ibro-obliteration of the intrahepatic and/or extrahepatic bile ducts.

2 sulting in dramatic and rapid enlargement of extrahepatic bile ducts.

3 pithelial malignant neoplasm of the liver or extrahepatic bile ducts.

4 mechanistically linked to obstruction of the extrahepatic bile ducts.

5 he inflammatory and fibrosing obstruction of extrahepatic bile ducts.

6 ter than 90% mortality due to obstruction of extrahepatic bile ducts.

7 en benign and malign lesions in intraluminal extrahepatic bile ducts.

8 by age at surgery and anatomy of the atretic extrahepatic bile ducts.

9 flammation and fibrosis of the intra- and/or extrahepatic bile ducts.

10 Sar among blood, hepatocytes, and intra- and extrahepatic bile ducts.

11 Carcinomas of the extrahepatic bile ducts, ampulla of Vater, and duodenum

12 SC were managed with either resection of the extrahepatic bile ducts and long-term transhepatic stent

13 ancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally h

14 gallbladder, 588 intrahepatic bile duct, 753 extrahepatic bile duct, and 458 ampulla of Vater cancer

15 h biliary tract cancer (237 gallbladder, 127 extrahepatic bile duct, and 47 ampulla of Vater), 895 wi

16 e livers and were the most abundant cells in extrahepatic bile ducts at the time of obstruction.

17 However, no associations were observed for extrahepatic bile duct cancer (EHBDC) or ampulla of Vate

18 gkin lymphoma (P < .001) and gallbladder and extrahepatic bile duct cancer (P = .01) was observed.

19 eased risk of gallbladder, intrahepatic, and extrahepatic bile duct cancer compared with the general

20 higher: 100% for gallbladder cancer, 97% of extrahepatic bile duct cancer, 91% of ampula of Vater ca

21 Carriers also have increased risk of extrahepatic bile duct cancer.

22 the body and tail of pancreas, cancer of the extrahepatic bile duct, cancer of the gallbladder, and c

23 d cholangiocytes, that line intrahepatic and extrahepatic bile ducts, contribute substantially to bil

24 ddition, the gall bladder was absent and the extrahepatic bile duct could not be identified.

25 Visualization of pancreatic and extrahepatic bile ducts (divided in five duct segments p

26 In extrahepatic bile duct (EHBD) cholangiopathies, includin

27 mouse has revealed that gallbladder (GB) and extrahepatic bile duct (EHBD) development is exquisitely

28 ls residing in the submucosal compartment of extrahepatic bile ducts (EHBDs).

29 derived from ductal tissue located outside (extrahepatic bile ducts; EHBDs) or inside the liver (int

30 of birth, microdissected the gallbladder and extrahepatic bile ducts en bloc 3, 7, and 14 days later,

31 and active caspase-3 staining in livers and extrahepatic bile ducts from Balb/c mice infected with R

32 breast, colorectum, endometrium, oesophagus, extrahepatic bile duct, gallbladder, head and neck, kidn

33 Intra- and extrahepatic bile duct (IHBD and EHBD) irregularities we

34 epatic bile duct in 25 (100%), the recipient extrahepatic bile duct in 17 of 18 (94%), and the anasto

35 c bile ducts in 23 (92%) patients, the donor extrahepatic bile duct in 25 (100%), the recipient extra

36 m an association between age and size of the extrahepatic bile duct in an asymptomatic adult populati

37 c ducts in 11 patients and in the intra- and extrahepatic bile ducts in eight patients.

38 flammatory cholangiopathy that obstructs the extrahepatic bile ducts in young infants.

39 apping in mice, we provide evidence that the extrahepatic bile duct is compartmentalized.

40 eriductular fibrosis of the intrahepatic and extrahepatic bile ducts leading to strictures, bacterial

41 inflammatory process that affects intra- and extrahepatic bile ducts, leading to fibrosis and obliter

42 tal stents compared with patients with other extrahepatic bile duct malignant diseases and patients t

43 cholangiocarcinoma (n = 11) or by secondary extrahepatic bile duct malignant tumors (n = 11) were tr

44 ary atresia is a neonatal liver disease with extrahepatic bile duct obstruction and progressive liver

45 ered or partially covered) for palliation of extrahepatic bile duct obstruction initially is more exp

46 related to total bilirubin, indicating that extrahepatic bile duct obstruction leads to down-regulat

47 doscopic stents are placed for palliation of extrahepatic bile duct obstruction.

48 primed CD8(+) cells preferentially homed to extrahepatic bile ducts of neonatal mice and invaded the

49 role of T lymphocytes in the destruction of extrahepatic bile ducts of neonatal mice using an experi

50 autoimmune disorder of the intrahepatic and extrahepatic bile ducts of unclear etiology.

51 f cancers that arise in either the intra- or extrahepatic bile ducts or the gallbladder.

52 f CD4(+) and CD8(+) T cells within liver and extrahepatic bile duct remnant tissues, indicating the p

53 Vbeta repertoire of T cells from the liver, extrahepatic bile duct remnants, and peripheral blood of

54 ed by lymphadenectomy (67%) and sometimes by extrahepatic bile duct resection (23%).

55 Extrahepatic bile duct resection with hepaticoenterostom

56 progressive fibroinflammatory obstruction of extrahepatic bile ducts that presents as neonatal choles

57 truction of segments or the entire length of extrahepatic bile ducts, the timely pursuit of hepatopor

58 sverse and anteroposterior dimensions of the extrahepatic bile duct were measured proximally at the p

59 The density of lesions along extrahepatic bile ducts were measured and compared with

60 epithelial cells lining the intrahepatic and extrahepatic bile ducts, which are central to the pathog

61 gs, spleen, liver, lymph nodes, pancreas and extrahepatic bile duct with potential for recurrence and

62 from biliary epithelial cells of intra- and extrahepatic bile ducts with dismal prognosis and few no

63 epithelial and subepithelial compartments of extrahepatic bile ducts, with onset within 3 days and pe